Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 AlteredExpression group BEFREE These findings establish RSK2 as an obligate participant of ERα-mediated transcriptional programs, tumorigenesis, and divergent patient responses to antiestrogen therapies.<b>Significance:</b> Nuclear accumulation of active RSK drives a protumorigenic transcriptional program and renders ER<sup>+</sup> breast cancer susceptible to endocrine-based therapies.<i>Cancer Res; 78(8); 2014-25.©2018 AACR</i>. 29351904 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE Although the RSKs have a high degree of sequence homology, their functional differences in cancer are of great interest. 28718440 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 AlteredExpression group BEFREE The expression of RSK1 to -3 were separately examined in human breast cancer tissues (normal, n=33; cancer, n=112) using quantitative real-time polymerase chain reaction (Q-PCR) and immunohistochemistry. 26977024 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE p90 ribosomal S6 kinase (p90RSK) constitutes a family of serine/threonine kinases that have been shown to be involved in cell proliferation of various malignancies via direct or indirect effects on the cell-cycle machinery. 27236820 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE Our results demonstrate that RSK is a major contributor to the TNBC metastatic program and provide preclinical proof-of-concept for the efficacy of the novel SL0101 analogue in vivo Mol Cancer Ther; 15(11); 2598-608.©2016 AACR. 27528706 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells. 26011941 2015
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE Taken together, these results indicate that the phosphorylation of EphA2 at Ser-897 is controlled by RSK and the RSK-EphA2 axis might contribute to cell motility and promote tumour malignant progression. 26158630 2015
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE P90RSK silencing using siRNA did not affect the cancer cell's response to doxorubicin, and the expression of phospho-p90RSK was highly correlated with other Ras/Raf/ERK pathway activation. 23216670 2012